QQQ   385.05 (-0.58%)
AAPL   192.32 (-0.57%)
MSFT   368.80 (-1.00%)
META   317.45 (-0.26%)
GOOGL   130.02 (-0.74%)
AMZN   144.52 (-1.61%)
TSLA   239.37 (+0.27%)
NVDA   455.03 (-2.28%)
NIO   7.76 (+4.44%)
BABA   71.51 (-1.20%)
AMD   116.82 (-1.32%)
T   16.95 (-1.57%)
F   10.70 (+0.94%)
MU   73.13 (-0.76%)
CGC   0.70 (+4.49%)
GE   119.82 (-0.34%)
DIS   91.51 (+0.79%)
AMC   6.79 (-3.28%)
PFE   28.81 (-1.00%)
PYPL   59.53 (+2.78%)
XOM   99.11 (-1.32%)
QQQ   385.05 (-0.58%)
AAPL   192.32 (-0.57%)
MSFT   368.80 (-1.00%)
META   317.45 (-0.26%)
GOOGL   130.02 (-0.74%)
AMZN   144.52 (-1.61%)
TSLA   239.37 (+0.27%)
NVDA   455.03 (-2.28%)
NIO   7.76 (+4.44%)
BABA   71.51 (-1.20%)
AMD   116.82 (-1.32%)
T   16.95 (-1.57%)
F   10.70 (+0.94%)
MU   73.13 (-0.76%)
CGC   0.70 (+4.49%)
GE   119.82 (-0.34%)
DIS   91.51 (+0.79%)
AMC   6.79 (-3.28%)
PFE   28.81 (-1.00%)
PYPL   59.53 (+2.78%)
XOM   99.11 (-1.32%)
QQQ   385.05 (-0.58%)
AAPL   192.32 (-0.57%)
MSFT   368.80 (-1.00%)
META   317.45 (-0.26%)
GOOGL   130.02 (-0.74%)
AMZN   144.52 (-1.61%)
TSLA   239.37 (+0.27%)
NVDA   455.03 (-2.28%)
NIO   7.76 (+4.44%)
BABA   71.51 (-1.20%)
AMD   116.82 (-1.32%)
T   16.95 (-1.57%)
F   10.70 (+0.94%)
MU   73.13 (-0.76%)
CGC   0.70 (+4.49%)
GE   119.82 (-0.34%)
DIS   91.51 (+0.79%)
AMC   6.79 (-3.28%)
PFE   28.81 (-1.00%)
PYPL   59.53 (+2.78%)
XOM   99.11 (-1.32%)
QQQ   385.05 (-0.58%)
AAPL   192.32 (-0.57%)
MSFT   368.80 (-1.00%)
META   317.45 (-0.26%)
GOOGL   130.02 (-0.74%)
AMZN   144.52 (-1.61%)
TSLA   239.37 (+0.27%)
NVDA   455.03 (-2.28%)
NIO   7.76 (+4.44%)
BABA   71.51 (-1.20%)
AMD   116.82 (-1.32%)
T   16.95 (-1.57%)
F   10.70 (+0.94%)
MU   73.13 (-0.76%)
CGC   0.70 (+4.49%)
GE   119.82 (-0.34%)
DIS   91.51 (+0.79%)
AMC   6.79 (-3.28%)
PFE   28.81 (-1.00%)
PYPL   59.53 (+2.78%)
XOM   99.11 (-1.32%)

Heron Therapeutics Stock Price, News & Analysis (NASDAQ:HRTX)

$1.44
-0.01 (-0.69%)
(As of 12/6/2023 ET)
Compare
Today's Range
$1.43
$1.52
50-Day Range
$0.54
$1.50
52-Week Range
$0.50
$3.41
Volume
2.11 million shs
Average Volume
2.35 million shs
Market Capitalization
$216.11 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.00

Heron Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
386.1% Upside
$7.00 Price Target
Short Interest
Bearish
11.72% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.96
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Acquiring Shares
$260,650 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.88) to ($0.39) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.38 out of 5 stars

Medical Sector

205th out of 955 stocks

Pharmaceutical Preparations Industry

66th out of 400 stocks


HRTX stock logo

About Heron Therapeutics Stock (NASDAQ:HRTX)

Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; HTX-019, an investigational agent for the prevention of postoperative nausea and vomiting; and HTX-034 for postoperative pain management, as well as is in Phase Ib/II clinical study in patients undergoing bunionectomy. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.

HRTX Stock Price History

HRTX Stock News Headlines

Why Heron Therapeutics Is A Compelling Buy Into 2024
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
Q3 2023 Heron Therapeutics Inc Earnings Call
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
Q2 2023 Heron Therapeutics Inc Earnings Call
See More Headlines
Receive HRTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Heron Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/23/2023
Today
12/06/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/28/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:HRTX
Employees
203
Year Founded
1983

Price Target and Rating

Average Stock Price Target
$7.00
High Stock Price Target
$10.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+386.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-182,020,000.00
Pretax Margin
-97.45%
Return on Equity
-21,127.62%

Debt

Sales & Book Value

Annual Sales
$107.67 million
Book Value
$0.11 per share

Miscellaneous

Free Float
140,468,000
Market Cap
$216.10 million
Optionable
Optionable
Beta
1.51

Social Links

The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

  • Mr. Craig Alexander Collard (Age 57)
    CEO & Director
  • Ms. Ira Duarte (Age 54)
    Executive VP & CFO
  • Ms. Lisa Peraza (Age 46)
    VP & Chief Accounting Officer
    Comp: $474.1k
  • Dr. Thomas B. Ottoboni Ph.D. (Age 64)
    Chief Scientific Officer and Senior VP of Pharmaceutical & Translational Sciences
  • Mr. Ryan Craig
    Vice President of Marketing
  • Mr. Sean T. Ristine (Age 53)
    Senior Vice President of Human Resources
  • Dr. Chris M. Storgard (Age 57)
    Chief Medical Officer
  • Mr. Robert Sullivan (Age 45)
    Senior VP of Oncology Care Franchise & Commercial Operations
  • Dr. William P. Forbes Pharm. D. (Age 61)
    Pharm.D., Executive VP & Chief Development Officer
  • Jeff Cohn
    Executive Director, Assistant General Counsel & Assistant Secretary














HRTX Stock Analysis - Frequently Asked Questions

Should I buy or sell Heron Therapeutics stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Heron Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" HRTX shares.
View HRTX analyst ratings
or view top-rated stocks.

What is Heron Therapeutics' stock price target for 2024?

3 brokers have issued 1-year target prices for Heron Therapeutics' shares. Their HRTX share price targets range from $4.00 to $10.00. On average, they predict the company's share price to reach $7.00 in the next twelve months. This suggests a possible upside of 386.1% from the stock's current price.
View analysts price targets for HRTX
or view top-rated stocks among Wall Street analysts.

How have HRTX shares performed in 2023?

Heron Therapeutics' stock was trading at $2.50 at the start of the year. Since then, HRTX shares have decreased by 42.4% and is now trading at $1.44.
View the best growth stocks for 2023 here
.

When is Heron Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 28th 2024.
View our HRTX earnings forecast
.

How were Heron Therapeutics' earnings last quarter?

Heron Therapeutics, Inc. (NASDAQ:HRTX) announced its quarterly earnings results on Thursday, March, 23rd. The biotechnology company reported ($0.17) EPS for the quarter, topping the consensus estimate of ($0.25) by $0.08. The biotechnology company had revenue of $30 million for the quarter, compared to the consensus estimate of $27.24 million. Heron Therapeutics had a negative net margin of 97.45% and a negative trailing twelve-month return on equity of 21,127.62%. The company's revenue was up 44.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.54) EPS.

What ETFs hold Heron Therapeutics' stock?

ETFs with the largest weight of Heron Therapeutics (NASDAQ:HRTX) stock in their portfolio include Jacob Forward ETF (JFWD) and Invesco Nasdaq Future Gen 200 ETF (QQQS).Simplify Propel Opportunities ETF (SURI).

What other stocks do shareholders of Heron Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Heron Therapeutics investors own include Micron Technology (MU), Pfizer (PFE), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), NVIDIA (NVDA), Editas Medicine (EDIT), Immunomedics (IMMU), bluebird bio (BLUE), AT&T (T) and Amarin (AMRN).

Who are Heron Therapeutics' major shareholders?

Heron Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Rubric Capital Management LP (18.98%), JW Asset Management LLC (1.71%), Tejara Capital Ltd (1.50%), Tejara Capital Ltd (1.50%), Adage Capital Partners GP L.L.C. (1.42%) and New York State Common Retirement Fund (0.78%). Insiders that own company stock include Adam Morgan, Craig A Collard, Craig A Johnson, David Leslie Szekeres, Ira Duarte, Kimberly Manhard, Waage Christian and William P Forbes.
View institutional ownership trends
.

How do I buy shares of Heron Therapeutics?

Shares of HRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

Does Heron Therapeutics have any subsidiaries?
The following companies are subsidiares of Heron Therapeutics: Heron Therapeutics B.V..
Read More
This page (NASDAQ:HRTX) was last updated on 12/6/2023 by MarketBeat.com Staff

My Account -